All data are based on the daily closing price as of October 6, 2025
s

Samsung Biologics

207940.KO
713.65 USD
0.67
+0.09%

Overview

Last close
713.65 usd
Market cap
50.79B usd
52 week high
761.21 usd
52 week low
522.84 usd
Target price
707.19 usd

Valuation

P/E
N/A
Forward P/E
37.1747
Price/Sales
14.2724
Price/Book Value
6.2201
Enterprise Value
50.88B usd
EV/Revenue
14.2981
EV/EBITDA
31.742

Key financials

Revenue TTM
3.56B usd
Gross Profit TTM
1.87B usd
EBITDA TTM
1.61B usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
13.13B usd
Net debt
465.98M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
  • Symbol
    207940.KO
  • Exchange
    KO
  • Isin
    KR7207940008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. John Chongbo Rim
  • Headquarter
    Incheon
  • Web site
    https://samsungbiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top